• Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary and rapidly evolving type of adoptive cell immunotherapy that has shown tremendous promise in leveraging the body’s own immune system to direct an antitumor response.
  
  
• CST has developed a panel of detection reagents that are designed to recognize a broad range of CARs: Anti-CAR linker antibodies.
  
  
• These first-to-market reagents can be incorporated into multiparametric flow panels for monitoring CAR expression, trafficking, and persistence in pre-clinical models.
  

 

Watch the video recap of our poster from AACR 2023 to discover how the immunosuppressive tumor microenvironment limits the efficacy of current CAR T-cell therapies and find out how these challenges are being addressed. 

Explore the anit-CAR Linker products, including available conjugates:

WEBINAR: Novel Antibodies for the Characterization of CAR-T Cells

In this webinar, viewers will:

• Learn ways to avoid pitfalls when characterizing CAR-T cells in your development workflow.
• See how the novel anti-CAR linker antibodies detect a broad range of scFv-based CARs.
• Explore how G4S and Whitlow linker CAR antibodies facilitate the detection of CARs in multiparametric flow panels.
• Discover how to save time by using one antibody to examine your entire panel of CARs.